| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 269 | 2023 | 1180 | 29.780 |
Why?
|
| Stroke Volume | 208 | 2023 | 586 | 18.630 |
Why?
|
| Tetrazoles | 92 | 2023 | 160 | 10.940 |
Why?
|
| Aminobutyrates | 76 | 2023 | 94 | 9.920 |
Why?
|
| Ventricular Function, Left | 90 | 2022 | 481 | 8.740 |
Why?
|
| Angiotensin Receptor Antagonists | 80 | 2023 | 155 | 8.390 |
Why?
|
| Biphenyl Compounds | 99 | 2023 | 184 | 6.550 |
Why?
|
| Myocardium | 83 | 2022 | 1204 | 6.100 |
Why?
|
| Valsartan | 79 | 2023 | 99 | 6.020 |
Why?
|
| Enalapril | 42 | 2023 | 86 | 5.890 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 51 | 2023 | 202 | 4.910 |
Why?
|
| Ventricular Dysfunction, Left | 37 | 2023 | 277 | 4.640 |
Why?
|
| Hypertrophy, Left Ventricular | 29 | 2022 | 140 | 4.340 |
Why?
|
| Diastole | 45 | 2022 | 161 | 4.300 |
Why?
|
| Natriuretic Peptide, Brain | 38 | 2023 | 101 | 4.200 |
Why?
|
| Ventricular Remodeling | 30 | 2022 | 318 | 4.110 |
Why?
|
| Baroreflex | 9 | 2022 | 20 | 3.830 |
Why?
|
| Peptide Fragments | 37 | 2022 | 483 | 3.540 |
Why?
|
| Heart Ventricles | 53 | 2022 | 738 | 3.370 |
Why?
|
| Neprilysin | 30 | 2022 | 55 | 3.280 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 38 | 2020 | 95 | 3.250 |
Why?
|
| Electric Stimulation Therapy | 8 | 2022 | 147 | 3.230 |
Why?
|
| Drug Combinations | 70 | 2023 | 304 | 3.130 |
Why?
|
| Hospitalization | 61 | 2021 | 978 | 3.060 |
Why?
|
| Extracellular Matrix | 18 | 2023 | 493 | 3.050 |
Why?
|
| Aged | 193 | 2022 | 14862 | 2.930 |
Why?
|
| Humans | 332 | 2023 | 68618 | 2.590 |
Why?
|
| Myocardial Contraction | 51 | 2018 | 383 | 2.590 |
Why?
|
| Biomarkers | 45 | 2023 | 1593 | 2.540 |
Why?
|
| Hypertension | 34 | 2022 | 1535 | 2.530 |
Why?
|
| Hemodynamics | 36 | 2022 | 705 | 2.510 |
Why?
|
| Prognosis | 67 | 2023 | 2093 | 2.380 |
Why?
|
| Heart | 36 | 2018 | 850 | 2.370 |
Why?
|
| Ventricular Pressure | 18 | 2022 | 82 | 2.360 |
Why?
|
| Male | 254 | 2023 | 37321 | 2.350 |
Why?
|
| Echocardiography | 44 | 2021 | 515 | 2.240 |
Why?
|
| Female | 242 | 2023 | 38074 | 2.240 |
Why?
|
| Middle Aged | 178 | 2022 | 21147 | 2.220 |
Why?
|
| Cardiomegaly | 30 | 2020 | 213 | 2.200 |
Why?
|
| Collagen | 21 | 2023 | 636 | 2.180 |
Why?
|
| Systole | 28 | 2020 | 149 | 2.110 |
Why?
|
| Blood Pressure | 43 | 2021 | 1451 | 2.090 |
Why?
|
| Heart Failure, Diastolic | 9 | 2014 | 14 | 1.970 |
Why?
|
| Prospective Studies | 58 | 2022 | 3705 | 1.690 |
Why?
|
| Treatment Outcome | 77 | 2023 | 7029 | 1.660 |
Why?
|
| Monitoring, Physiologic | 6 | 2017 | 219 | 1.490 |
Why?
|
| Randomized Controlled Trials as Topic | 27 | 2022 | 931 | 1.470 |
Why?
|
| Myocytes, Cardiac | 15 | 2021 | 442 | 1.440 |
Why?
|
| Defibrillators, Implantable | 8 | 2021 | 329 | 1.430 |
Why?
|
| Fibrosis | 17 | 2022 | 371 | 1.390 |
Why?
|
| Mitral Valve Insufficiency | 21 | 2018 | 99 | 1.390 |
Why?
|
| Hypertension, Pulmonary | 6 | 2021 | 232 | 1.380 |
Why?
|
| Osteonectin | 8 | 2020 | 69 | 1.340 |
Why?
|
| Cause of Death | 24 | 2020 | 241 | 1.330 |
Why?
|
| Aged, 80 and over | 54 | 2022 | 4848 | 1.320 |
Why?
|
| Cardiac Catheterization | 12 | 2021 | 419 | 1.290 |
Why?
|
| Double-Blind Method | 45 | 2021 | 1738 | 1.270 |
Why?
|
| Connectin | 3 | 2021 | 14 | 1.250 |
Why?
|
| Quality of Life | 25 | 2022 | 1515 | 1.220 |
Why?
|
| Atrial Fibrillation | 13 | 2022 | 249 | 1.210 |
Why?
|
| Natriuretic Peptides | 7 | 2022 | 12 | 1.190 |
Why?
|
| Matrix Metalloproteinases | 10 | 2013 | 223 | 1.170 |
Why?
|
| Time Factors | 56 | 2021 | 4655 | 1.170 |
Why?
|
| Risk Assessment | 25 | 2021 | 2007 | 1.150 |
Why?
|
| Animals | 127 | 2023 | 20881 | 1.140 |
Why?
|
| Fibrillar Collagens | 4 | 2020 | 49 | 1.140 |
Why?
|
| Death, Sudden, Cardiac | 11 | 2021 | 141 | 1.110 |
Why?
|
| Follow-Up Studies | 37 | 2021 | 3259 | 1.080 |
Why?
|
| Tachycardia, Supraventricular | 12 | 1995 | 73 | 1.020 |
Why?
|
| Procollagen | 5 | 2016 | 31 | 1.000 |
Why?
|
| Myocardial Infarction | 13 | 2020 | 807 | 0.970 |
Why?
|
| Pulmonary Wedge Pressure | 6 | 2019 | 102 | 0.960 |
Why?
|
| Risk Factors | 46 | 2021 | 5731 | 0.960 |
Why?
|
| Carotid Sinus | 2 | 2016 | 5 | 0.930 |
Why?
|
| Survival Rate | 28 | 2021 | 1056 | 0.900 |
Why?
|
| Chronic Disease | 25 | 2021 | 1330 | 0.890 |
Why?
|
| Kidney | 10 | 2022 | 945 | 0.840 |
Why?
|
| Renin-Angiotensin System | 7 | 2018 | 79 | 0.820 |
Why?
|
| Exercise Tolerance | 7 | 2021 | 75 | 0.800 |
Why?
|
| Heart Rate | 14 | 2019 | 568 | 0.800 |
Why?
|
| Aging | 9 | 2022 | 911 | 0.800 |
Why?
|
| Cardiac Pacing, Artificial | 9 | 2021 | 174 | 0.790 |
Why?
|
| Mitral Valve | 11 | 2018 | 166 | 0.770 |
Why?
|
| Proportional Hazards Models | 24 | 2021 | 792 | 0.770 |
Why?
|
| Pressoreceptors | 1 | 2021 | 15 | 0.770 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 11 | 2021 | 25 | 0.750 |
Why?
|
| Predictive Value of Tests | 15 | 2021 | 1465 | 0.730 |
Why?
|
| Sex Characteristics | 1 | 2022 | 295 | 0.710 |
Why?
|
| Glycation End Products, Advanced | 3 | 2017 | 125 | 0.700 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2019 | 1085 | 0.700 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2019 | 10 | 0.670 |
Why?
|
| Lysine | 2 | 2017 | 96 | 0.670 |
Why?
|
| United States | 25 | 2021 | 7367 | 0.660 |
Why?
|
| Coronary Disease | 5 | 2017 | 358 | 0.660 |
Why?
|
| Drug Approval | 2 | 2018 | 50 | 0.650 |
Why?
|
| Pulmonary Artery | 9 | 2022 | 323 | 0.640 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2017 | 307 | 0.620 |
Why?
|
| Health Care Costs | 1 | 2021 | 346 | 0.610 |
Why?
|
| Disease Progression | 17 | 2019 | 1038 | 0.610 |
Why?
|
| Diuretics | 10 | 2022 | 97 | 0.610 |
Why?
|
| Adrenergic beta-Antagonists | 12 | 2020 | 189 | 0.600 |
Why?
|
| Fibroblasts | 10 | 2023 | 902 | 0.590 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 6 | 2014 | 85 | 0.590 |
Why?
|
| Cardiomyopathies | 7 | 2001 | 167 | 0.590 |
Why?
|
| Coronary Circulation | 11 | 2000 | 136 | 0.580 |
Why?
|
| Glomerular Filtration Rate | 10 | 2018 | 274 | 0.580 |
Why?
|
| Diabetes Mellitus | 6 | 2022 | 694 | 0.580 |
Why?
|
| Atrial Function, Left | 4 | 2021 | 10 | 0.580 |
Why?
|
| Cats | 22 | 2015 | 292 | 0.580 |
Why?
|
| Sex Factors | 13 | 2022 | 1266 | 0.580 |
Why?
|
| Protease Inhibitors | 4 | 2020 | 76 | 0.580 |
Why?
|
| Hospice Care | 1 | 2017 | 29 | 0.580 |
Why?
|
| Sympathectomy | 2 | 2014 | 24 | 0.570 |
Why?
|
| Kidney Diseases | 3 | 2020 | 307 | 0.570 |
Why?
|
| Cardiotonic Agents | 8 | 2020 | 71 | 0.560 |
Why?
|
| MicroRNAs | 4 | 2019 | 447 | 0.560 |
Why?
|
| Patient Selection | 3 | 2018 | 592 | 0.560 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2018 | 164 | 0.560 |
Why?
|
| Mice | 32 | 2023 | 8474 | 0.550 |
Why?
|
| Cardiac Resynchronization Therapy | 4 | 2021 | 119 | 0.550 |
Why?
|
| Clinical Protocols | 1 | 2017 | 172 | 0.550 |
Why?
|
| Benzimidazoles | 6 | 2020 | 128 | 0.550 |
Why?
|
| Cardiomyopathy, Dilated | 9 | 2019 | 106 | 0.540 |
Why?
|
| Heart Diseases | 3 | 2021 | 276 | 0.540 |
Why?
|
| Prosthesis Implantation | 2 | 2016 | 83 | 0.540 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2018 | 536 | 0.540 |
Why?
|
| Cardiography, Impedance | 1 | 2015 | 14 | 0.530 |
Why?
|
| Heart-Assist Devices | 4 | 2021 | 221 | 0.530 |
Why?
|
| Echocardiography, Doppler | 13 | 2018 | 87 | 0.530 |
Why?
|
| Elasticity | 10 | 2015 | 103 | 0.530 |
Why?
|
| Telemetry | 1 | 2015 | 23 | 0.530 |
Why?
|
| Mortality | 8 | 2021 | 163 | 0.530 |
Why?
|
| Retrospective Studies | 23 | 2022 | 7277 | 0.530 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 7 | 2021 | 59 | 0.520 |
Why?
|
| Calcium | 10 | 2012 | 929 | 0.520 |
Why?
|
| RNA | 2 | 2014 | 171 | 0.520 |
Why?
|
| Aortic Valve Stenosis | 8 | 2011 | 177 | 0.520 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2015 | 24 | 0.520 |
Why?
|
| Tetralogy of Fallot | 1 | 2015 | 43 | 0.520 |
Why?
|
| Patient Readmission | 5 | 2020 | 267 | 0.510 |
Why?
|
| Case-Control Studies | 13 | 2022 | 1553 | 0.500 |
Why?
|
| Autonomic Nervous System | 2 | 2012 | 31 | 0.500 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2021 | 1745 | 0.490 |
Why?
|
| Palliative Care | 1 | 2017 | 271 | 0.490 |
Why?
|
| Severity of Illness Index | 12 | 2021 | 1851 | 0.490 |
Why?
|
| Troponin T | 3 | 2021 | 16 | 0.480 |
Why?
|
| Comorbidity | 13 | 2021 | 1426 | 0.480 |
Why?
|
| Protein Biosynthesis | 4 | 2012 | 181 | 0.480 |
Why?
|
| Cardiovascular Diseases | 9 | 2019 | 940 | 0.470 |
Why?
|
| Swine | 24 | 2011 | 672 | 0.470 |
Why?
|
| Mice, Inbred C57BL | 19 | 2022 | 2791 | 0.470 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2014 | 17 | 0.470 |
Why?
|
| Isoxazoles | 1 | 2014 | 22 | 0.470 |
Why?
|
| Gene Expression Regulation | 5 | 2019 | 1293 | 0.460 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 4 | 2021 | 11 | 0.460 |
Why?
|
| Single-Blind Method | 9 | 2019 | 249 | 0.450 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2014 | 44 | 0.450 |
Why?
|
| Thiophenes | 1 | 2014 | 76 | 0.450 |
Why?
|
| Obesity | 9 | 2021 | 1076 | 0.450 |
Why?
|
| Disease Models, Animal | 22 | 2022 | 2550 | 0.440 |
Why?
|
| Pyrimidines | 3 | 2020 | 178 | 0.440 |
Why?
|
| Heart Valve Prosthesis | 12 | 1994 | 222 | 0.440 |
Why?
|
| Morbidity | 10 | 2020 | 130 | 0.430 |
Why?
|
| Receptors, Adrenergic, beta | 7 | 2001 | 153 | 0.430 |
Why?
|
| Microtubules | 7 | 2008 | 104 | 0.430 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2013 | 61 | 0.410 |
Why?
|
| Body Mass Index | 6 | 2022 | 867 | 0.410 |
Why?
|
| Exercise | 3 | 2018 | 658 | 0.410 |
Why?
|
| Digoxin | 4 | 2020 | 24 | 0.400 |
Why?
|
| Global Health | 7 | 2021 | 136 | 0.400 |
Why?
|
| Enzyme Induction | 1 | 2012 | 119 | 0.400 |
Why?
|
| Proteolysis | 1 | 2012 | 97 | 0.400 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 74 | 0.400 |
Why?
|
| Adult | 35 | 2022 | 21403 | 0.390 |
Why?
|
| Cohort Studies | 10 | 2021 | 2358 | 0.390 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2015 | 284 | 0.380 |
Why?
|
| Benzenesulfonates | 3 | 2007 | 30 | 0.380 |
Why?
|
| Age Factors | 15 | 2021 | 1864 | 0.380 |
Why?
|
| Frailty | 2 | 2022 | 34 | 0.380 |
Why?
|
| Disease Management | 4 | 2019 | 248 | 0.370 |
Why?
|
| Coronary Artery Disease | 5 | 2018 | 696 | 0.370 |
Why?
|
| Pacemaker, Artificial | 4 | 2019 | 157 | 0.360 |
Why?
|
| Dogs | 27 | 2001 | 490 | 0.350 |
Why?
|
| Myocardial Ischemia | 2 | 2019 | 172 | 0.350 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2021 | 207 | 0.350 |
Why?
|
| Takotsubo Cardiomyopathy | 3 | 2015 | 14 | 0.350 |
Why?
|
| Valine | 6 | 2014 | 43 | 0.340 |
Why?
|
| Mice, Transgenic | 6 | 2014 | 1033 | 0.340 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 212 | 0.340 |
Why?
|
| Spironolactone | 3 | 2020 | 13 | 0.340 |
Why?
|
| Veterans | 1 | 2017 | 904 | 0.340 |
Why?
|
| Blood Pressure Determination | 3 | 2019 | 152 | 0.340 |
Why?
|
| Piperazines | 3 | 2007 | 206 | 0.340 |
Why?
|
| Retinoids | 3 | 1999 | 122 | 0.340 |
Why?
|
| Antihypertensive Agents | 8 | 2019 | 498 | 0.330 |
Why?
|
| Pyrazoles | 2 | 2020 | 190 | 0.330 |
Why?
|
| Electrodes, Implanted | 2 | 2021 | 98 | 0.330 |
Why?
|
| Incidence | 10 | 2021 | 1603 | 0.320 |
Why?
|
| Prediabetic State | 2 | 2022 | 48 | 0.320 |
Why?
|
| Diabetic Cardiomyopathies | 3 | 2019 | 17 | 0.320 |
Why?
|
| Inflammation Mediators | 3 | 2020 | 244 | 0.320 |
Why?
|
| Chagas Cardiomyopathy | 2 | 2018 | 3 | 0.320 |
Why?
|
| Tissue Engineering | 3 | 2023 | 212 | 0.310 |
Why?
|
| Heart Atria | 5 | 2016 | 206 | 0.310 |
Why?
|
| Prevalence | 10 | 2020 | 1619 | 0.310 |
Why?
|
| Mice, Knockout | 12 | 2018 | 1692 | 0.310 |
Why?
|
| Bundle-Branch Block | 2 | 2020 | 50 | 0.310 |
Why?
|
| Hypertrophy, Right Ventricular | 3 | 2012 | 21 | 0.310 |
Why?
|
| Heart Failure, Systolic | 3 | 2014 | 16 | 0.310 |
Why?
|
| Protein Precursors | 3 | 2020 | 105 | 0.310 |
Why?
|
| Heart Transplantation | 4 | 2020 | 328 | 0.310 |
Why?
|
| Heart Function Tests | 4 | 2008 | 33 | 0.300 |
Why?
|
| Ultrasonography | 6 | 2014 | 453 | 0.300 |
Why?
|
| Kidney Failure, Chronic | 3 | 2022 | 365 | 0.300 |
Why?
|
| Furosemide | 2 | 2019 | 45 | 0.300 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2018 | 24 | 0.300 |
Why?
|
| Tubulin | 5 | 2008 | 60 | 0.300 |
Why?
|
| Drug Therapy, Combination | 7 | 2017 | 649 | 0.300 |
Why?
|
| Terminology as Topic | 2 | 2006 | 141 | 0.300 |
Why?
|
| Tachycardia | 3 | 2011 | 53 | 0.290 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 2 | 2006 | 20 | 0.290 |
Why?
|
| Vasodilator Agents | 3 | 2022 | 138 | 0.290 |
Why?
|
| Cardiology | 2 | 2012 | 140 | 0.290 |
Why?
|
| Health Status Disparities | 3 | 2019 | 326 | 0.280 |
Why?
|
| Nitroprusside | 6 | 2003 | 42 | 0.280 |
Why?
|
| Ventricular Function | 7 | 2017 | 93 | 0.280 |
Why?
|
| Angiotensinogen | 2 | 2017 | 18 | 0.280 |
Why?
|
| Hydroxamic Acids | 4 | 2015 | 84 | 0.280 |
Why?
|
| TRPP Cation Channels | 2 | 2017 | 20 | 0.280 |
Why?
|
| Patient Outcome Assessment | 2 | 2018 | 42 | 0.280 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2021 | 161 | 0.270 |
Why?
|
| Cardiac Output | 9 | 2013 | 133 | 0.270 |
Why?
|
| Macrophages | 3 | 2020 | 647 | 0.270 |
Why?
|
| Angina Pectoris | 2 | 2015 | 61 | 0.270 |
Why?
|
| Muscle Contraction | 3 | 2021 | 210 | 0.270 |
Why?
|
| Rats | 12 | 2022 | 5300 | 0.270 |
Why?
|
| Implantable Neurostimulators | 2 | 2016 | 12 | 0.270 |
Why?
|
| Transcription Factors | 6 | 2015 | 753 | 0.260 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2005 | 116 | 0.260 |
Why?
|
| Fumarates | 4 | 2019 | 28 | 0.260 |
Why?
|
| Fibrinolysin | 2 | 2003 | 33 | 0.260 |
Why?
|
| Clinical Trials as Topic | 7 | 2018 | 848 | 0.260 |
Why?
|
| Myocardial Reperfusion Injury | 4 | 2018 | 84 | 0.260 |
Why?
|
| Signal Transduction | 13 | 2019 | 2689 | 0.260 |
Why?
|
| Nitrates | 2 | 2003 | 61 | 0.250 |
Why?
|
| Cardiac Output, Low | 2 | 2003 | 52 | 0.250 |
Why?
|
| Amides | 4 | 2019 | 86 | 0.250 |
Why?
|
| Cells, Cultured | 14 | 2023 | 2673 | 0.250 |
Why?
|
| Polycystic Kidney Diseases | 2 | 2015 | 39 | 0.250 |
Why?
|
| Vitamin A Deficiency | 4 | 2000 | 11 | 0.250 |
Why?
|
| Stroke | 5 | 2022 | 2163 | 0.250 |
Why?
|
| Isoproterenol | 8 | 1995 | 163 | 0.240 |
Why?
|
| Collagenases | 2 | 2006 | 34 | 0.240 |
Why?
|
| Phenotype | 9 | 2020 | 947 | 0.240 |
Why?
|
| Stress, Mechanical | 9 | 2023 | 208 | 0.240 |
Why?
|
| Surveys and Questionnaires | 7 | 2020 | 2800 | 0.240 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2014 | 33 | 0.240 |
Why?
|
| Proteomics | 4 | 2022 | 246 | 0.230 |
Why?
|
| Patient Admission | 2 | 2015 | 99 | 0.230 |
Why?
|
| Creatinine | 4 | 2018 | 243 | 0.230 |
Why?
|
| Potassium | 2 | 2021 | 168 | 0.220 |
Why?
|
| Walk Test | 3 | 2020 | 10 | 0.220 |
Why?
|
| Inflammation | 3 | 2021 | 1030 | 0.220 |
Why?
|
| Registries | 7 | 2020 | 733 | 0.220 |
Why?
|
| Heart Arrest | 2 | 2018 | 113 | 0.220 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2016 | 282 | 0.220 |
Why?
|
| Societies, Medical | 2 | 2018 | 403 | 0.220 |
Why?
|
| Renal Insufficiency | 2 | 2016 | 121 | 0.220 |
Why?
|
| Machine Learning | 2 | 2022 | 170 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 3 | 2021 | 504 | 0.210 |
Why?
|
| Acute Disease | 6 | 2012 | 658 | 0.210 |
Why?
|
| Myofibroblasts | 2 | 2014 | 60 | 0.210 |
Why?
|
| Europe | 6 | 2018 | 196 | 0.210 |
Why?
|
| Insulins | 1 | 2022 | 5 | 0.210 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 4 | 2005 | 59 | 0.210 |
Why?
|
| Hyperemia | 3 | 1998 | 14 | 0.210 |
Why?
|
| Angiotensins | 2 | 2022 | 16 | 0.210 |
Why?
|
| Biopsy | 3 | 2015 | 540 | 0.210 |
Why?
|
| In Vitro Techniques | 10 | 2003 | 765 | 0.210 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 209 | 0.200 |
Why?
|
| Muscle Proteins | 2 | 2012 | 94 | 0.200 |
Why?
|
| Meninges | 1 | 2022 | 7 | 0.200 |
Why?
|
| Cranial Sinuses | 1 | 2022 | 11 | 0.200 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2016 | 145 | 0.200 |
Why?
|
| Laminin | 2 | 2021 | 62 | 0.200 |
Why?
|
| Research Design | 4 | 2018 | 729 | 0.200 |
Why?
|
| Patient Discharge | 4 | 2017 | 294 | 0.200 |
Why?
|
| Myosin Heavy Chains | 3 | 2012 | 49 | 0.200 |
Why?
|
| Hypoglycemia | 1 | 2022 | 72 | 0.200 |
Why?
|
| Asia | 5 | 2019 | 59 | 0.190 |
Why?
|
| Integrin beta3 | 3 | 2012 | 35 | 0.190 |
Why?
|
| Feasibility Studies | 2 | 2021 | 652 | 0.190 |
Why?
|
| Aorta | 6 | 2012 | 316 | 0.190 |
Why?
|
| Tachycardia, Ventricular | 1 | 2023 | 153 | 0.190 |
Why?
|
| Organ Size | 6 | 2014 | 242 | 0.190 |
Why?
|
| Integrins | 4 | 2014 | 115 | 0.190 |
Why?
|
| Sarcomeres | 4 | 2003 | 32 | 0.190 |
Why?
|
| Time | 1 | 2021 | 57 | 0.190 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 80 | 0.190 |
Why?
|
| Models, Economic | 1 | 2021 | 69 | 0.190 |
Why?
|
| Analgesia, Epidural | 2 | 2000 | 40 | 0.190 |
Why?
|
| Vascular Remodeling | 1 | 2021 | 34 | 0.180 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2012 | 117 | 0.180 |
Why?
|
| Weight Reduction Programs | 1 | 2021 | 67 | 0.180 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2021 | 201 | 0.180 |
Why?
|
| Exercise Test | 5 | 2016 | 242 | 0.180 |
Why?
|
| United States Food and Drug Administration | 2 | 2018 | 131 | 0.180 |
Why?
|
| Uric Acid | 1 | 2020 | 37 | 0.180 |
Why?
|
| Immunoblotting | 4 | 2019 | 254 | 0.180 |
Why?
|
| Lymph Nodes | 1 | 2022 | 258 | 0.180 |
Why?
|
| Cost Savings | 1 | 2021 | 110 | 0.180 |
Why?
|
| Reference Values | 7 | 2007 | 579 | 0.180 |
Why?
|
| Blood Glucose | 3 | 2022 | 631 | 0.180 |
Why?
|
| Fontan Procedure | 1 | 2022 | 129 | 0.180 |
Why?
|
| Survival Analysis | 4 | 2016 | 714 | 0.180 |
Why?
|
| Gene Expression Regulation, Developmental | 5 | 2006 | 328 | 0.180 |
Why?
|
| Pneumonia | 1 | 2021 | 110 | 0.180 |
Why?
|
| Medicare | 3 | 2020 | 319 | 0.180 |
Why?
|
| RNA, Messenger | 9 | 2019 | 1664 | 0.180 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2011 | 89 | 0.180 |
Why?
|
| Electrocardiography | 8 | 2021 | 601 | 0.170 |
Why?
|
| Ubiquitination | 2 | 2011 | 85 | 0.170 |
Why?
|
| Electric Impedance | 1 | 2020 | 131 | 0.170 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 2 | 2018 | 22 | 0.170 |
Why?
|
| Calpain | 3 | 2011 | 205 | 0.170 |
Why?
|
| Aortic Valve Insufficiency | 3 | 1991 | 47 | 0.170 |
Why?
|
| Lymphangiogenesis | 1 | 2019 | 10 | 0.170 |
Why?
|
| Oligopeptides | 4 | 2009 | 152 | 0.170 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 1753 | 0.170 |
Why?
|
| Transducers, Pressure | 1 | 2019 | 14 | 0.170 |
Why?
|
| Cardiovascular Agents | 2 | 2017 | 82 | 0.170 |
Why?
|
| Cardiac Catheters | 1 | 2019 | 12 | 0.170 |
Why?
|
| Ventricular Function, Right | 2 | 2019 | 103 | 0.170 |
Why?
|
| Hemodynamic Monitoring | 1 | 2019 | 6 | 0.170 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 39 | 0.170 |
Why?
|
| Waiting Lists | 1 | 2020 | 104 | 0.170 |
Why?
|
| Pressure | 6 | 2012 | 252 | 0.170 |
Why?
|
| Formoterol Fumarate | 1 | 2019 | 25 | 0.170 |
Why?
|
| Recovery of Function | 3 | 2020 | 506 | 0.170 |
Why?
|
| Exome | 1 | 2019 | 20 | 0.160 |
Why?
|
| Xenopus Proteins | 1 | 1999 | 31 | 0.160 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 27 | 0.160 |
Why?
|
| Hospitals, University | 1 | 2019 | 169 | 0.160 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 77 | 0.160 |
Why?
|
| Proteins | 5 | 2011 | 474 | 0.160 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2018 | 6 | 0.160 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1998 | 48 | 0.160 |
Why?
|
| Geography | 2 | 2018 | 80 | 0.160 |
Why?
|
| Oxygen | 1 | 2020 | 386 | 0.160 |
Why?
|
| Propensity Score | 4 | 2021 | 117 | 0.160 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2018 | 18 | 0.160 |
Why?
|
| Pulmonary Fibrosis | 1 | 2020 | 157 | 0.160 |
Why?
|
| Pandemics | 1 | 2022 | 352 | 0.160 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2009 | 73 | 0.160 |
Why?
|
| Angiotensin II | 5 | 2015 | 220 | 0.160 |
Why?
|
| Dipeptides | 2 | 2009 | 89 | 0.160 |
Why?
|
| Renin | 2 | 2017 | 96 | 0.160 |
Why?
|
| Multimorbidity | 1 | 2018 | 7 | 0.160 |
Why?
|
| Electric Countershock | 2 | 2016 | 130 | 0.150 |
Why?
|
| Carotid Arteries | 1 | 2018 | 110 | 0.150 |
Why?
|
| Mutation | 3 | 2021 | 1213 | 0.150 |
Why?
|
| Income | 1 | 2019 | 167 | 0.150 |
Why?
|
| Cardiovascular System | 1 | 1998 | 85 | 0.150 |
Why?
|
| Cardiac Volume | 2 | 2011 | 21 | 0.150 |
Why?
|
| Podocytes | 1 | 2019 | 113 | 0.150 |
Why?
|
| Enzyme Activation | 6 | 2009 | 791 | 0.150 |
Why?
|
| Epilepsy | 1 | 2022 | 336 | 0.150 |
Why?
|
| Consensus | 1 | 2018 | 211 | 0.150 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2001 | 25 | 0.150 |
Why?
|
| Drug Administration Schedule | 5 | 2021 | 567 | 0.150 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2017 | 25 | 0.150 |
Why?
|
| Death, Sudden | 1 | 2017 | 24 | 0.150 |
Why?
|
| Protein Isoforms | 2 | 2015 | 246 | 0.150 |
Why?
|
| Phosphorylation | 4 | 2015 | 1200 | 0.150 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2019 | 134 | 0.150 |
Why?
|
| Circadian Rhythm | 1 | 2018 | 218 | 0.150 |
Why?
|
| Bupivacaine | 1 | 1997 | 27 | 0.140 |
Why?
|
| Diabetes Complications | 2 | 2018 | 249 | 0.140 |
Why?
|
| Social Behavior | 1 | 2018 | 164 | 0.140 |
Why?
|
| Viscosity | 3 | 2002 | 72 | 0.140 |
Why?
|
| Apoptosis | 6 | 2019 | 1641 | 0.140 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 211 | 0.140 |
Why?
|
| Hyperkalemia | 1 | 2017 | 21 | 0.140 |
Why?
|
| Microscopy, Electron, Scanning | 5 | 2002 | 236 | 0.140 |
Why?
|
| Models, Cardiovascular | 5 | 2009 | 133 | 0.140 |
Why?
|
| Insulin | 2 | 2019 | 619 | 0.140 |
Why?
|
| Multivariate Analysis | 5 | 2020 | 1046 | 0.140 |
Why?
|
| Diabetic Nephropathies | 1 | 2018 | 161 | 0.140 |
Why?
|
| Anesthetics, Local | 1 | 1997 | 83 | 0.140 |
Why?
|
| Public Health | 1 | 2018 | 201 | 0.140 |
Why?
|
| ADAMTS1 Protein | 1 | 2016 | 9 | 0.140 |
Why?
|
| American Heart Association | 1 | 2017 | 142 | 0.140 |
Why?
|
| Bayes Theorem | 1 | 2018 | 307 | 0.140 |
Why?
|
| DNA-Binding Proteins | 3 | 2000 | 700 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2018 | 311 | 0.140 |
Why?
|
| Blotting, Western | 4 | 2012 | 954 | 0.140 |
Why?
|
| Chordae Tendineae | 2 | 1992 | 7 | 0.140 |
Why?
|
| Hypotension | 4 | 2019 | 74 | 0.140 |
Why?
|
| Galectins | 1 | 2016 | 3 | 0.130 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2016 | 7 | 0.130 |
Why?
|
| Primary Prevention | 1 | 2017 | 115 | 0.130 |
Why?
|
| Galectin 3 | 1 | 2016 | 8 | 0.130 |
Why?
|
| Water-Electrolyte Balance | 1 | 1996 | 43 | 0.130 |
Why?
|
| Papillary Muscles | 4 | 2002 | 30 | 0.130 |
Why?
|
| Influenza A virus | 1 | 2015 | 13 | 0.130 |
Why?
|
| Lactosylceramides | 1 | 2016 | 27 | 0.130 |
Why?
|
| Electric Stimulation | 4 | 2015 | 218 | 0.130 |
Why?
|
| Analgesics | 1 | 1997 | 118 | 0.130 |
Why?
|
| Cytokines | 1 | 2020 | 866 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2018 | 402 | 0.130 |
Why?
|
| Mitochondria, Heart | 1 | 2016 | 53 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 955 | 0.130 |
Why?
|
| Proteinuria | 1 | 2016 | 136 | 0.130 |
Why?
|
| Activities of Daily Living | 2 | 2018 | 319 | 0.130 |
Why?
|
| Blood Proteins | 1 | 2016 | 94 | 0.130 |
Why?
|
| Myofibrils | 1 | 1995 | 35 | 0.130 |
Why?
|
| Enzyme Inhibitors | 4 | 2018 | 659 | 0.130 |
Why?
|
| Manometry | 1 | 2017 | 276 | 0.130 |
Why?
|
| Cell Separation | 5 | 2001 | 132 | 0.130 |
Why?
|
| Insurance Benefits | 1 | 2015 | 6 | 0.130 |
Why?
|
| Patient Dropouts | 1 | 2016 | 98 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 114 | 0.130 |
Why?
|
| Hospices | 1 | 2015 | 14 | 0.130 |
Why?
|
| Lung | 1 | 2020 | 849 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 56 | 0.130 |
Why?
|
| Compliance | 1 | 2015 | 26 | 0.130 |
Why?
|
| Blood Flow Velocity | 4 | 2008 | 172 | 0.130 |
Why?
|
| Influenza, Human | 1 | 2015 | 79 | 0.120 |
Why?
|
| Macrophages, Peritoneal | 1 | 2015 | 67 | 0.120 |
Why?
|
| Home Care Services | 1 | 2015 | 84 | 0.120 |
Why?
|
| Fluorobenzenes | 1 | 2014 | 10 | 0.120 |
Why?
|
| Dementia | 1 | 2016 | 158 | 0.120 |
Why?
|
| Myocarditis | 1 | 2015 | 49 | 0.120 |
Why?
|
| Weight Gain | 1 | 2015 | 135 | 0.120 |
Why?
|
| Biocompatible Materials | 2 | 2009 | 247 | 0.120 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2014 | 1 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 248 | 0.120 |
Why?
|
| Muscle Cells | 2 | 2005 | 30 | 0.120 |
Why?
|
| Health Status | 1 | 2017 | 429 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 142 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 116 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2022 | 2223 | 0.120 |
Why?
|
| Losartan | 3 | 2006 | 45 | 0.120 |
Why?
|
| Homeostasis | 2 | 2018 | 291 | 0.120 |
Why?
|
| Vaccination | 1 | 2015 | 189 | 0.120 |
Why?
|
| Mitochondria | 1 | 2019 | 643 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 504 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2016 | 340 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2014 | 141 | 0.110 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2007 | 178 | 0.110 |
Why?
|
| Colchicine | 4 | 2002 | 48 | 0.110 |
Why?
|
| In Situ Hybridization | 5 | 2000 | 201 | 0.110 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2014 | 90 | 0.110 |
Why?
|
| Parasympathetic Nervous System | 1 | 2013 | 14 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2015 | 158 | 0.110 |
Why?
|
| Neurotransmitter Agents | 2 | 2012 | 102 | 0.110 |
Why?
|
| Oxygen Consumption | 6 | 2016 | 258 | 0.110 |
Why?
|
| Anticoagulants | 3 | 2022 | 356 | 0.110 |
Why?
|
| Hypoxia | 2 | 2015 | 169 | 0.110 |
Why?
|
| Sympathetic Nervous System | 1 | 2013 | 81 | 0.110 |
Why?
|
| Cell Transdifferentiation | 1 | 2013 | 12 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2015 | 622 | 0.110 |
Why?
|
| Myosins | 1 | 2012 | 34 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2015 | 383 | 0.110 |
Why?
|
| Cell Proliferation | 4 | 2022 | 1174 | 0.110 |
Why?
|
| Algorithms | 1 | 2018 | 1196 | 0.110 |
Why?
|
| Muscles | 1 | 1993 | 158 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 3 | 2019 | 186 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2014 | 1040 | 0.100 |
Why?
|
| Kidney Function Tests | 4 | 2016 | 114 | 0.100 |
Why?
|
| Biomechanical Phenomena | 5 | 2008 | 368 | 0.100 |
Why?
|
| Substrate Specificity | 1 | 2013 | 234 | 0.100 |
Why?
|
| Dietary Fats | 1 | 2012 | 103 | 0.100 |
Why?
|
| Hospitals | 1 | 2014 | 265 | 0.100 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2012 | 2 | 0.100 |
Why?
|
| Xanthines | 1 | 2012 | 17 | 0.100 |
Why?
|
| Thermodilution | 1 | 1992 | 20 | 0.100 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2012 | 62 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 615 | 0.100 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1992 | 72 | 0.100 |
Why?
|
| Health Resources | 1 | 2012 | 76 | 0.100 |
Why?
|
| Endothelium, Vascular | 3 | 2016 | 371 | 0.100 |
Why?
|
| Cell Adhesion | 3 | 2012 | 324 | 0.100 |
Why?
|
| Verapamil | 1 | 1991 | 30 | 0.100 |
Why?
|
| Postoperative Complications | 3 | 2016 | 1615 | 0.100 |
Why?
|
| Osteopontin | 1 | 2011 | 28 | 0.100 |
Why?
|
| Hospital Costs | 1 | 2012 | 117 | 0.100 |
Why?
|
| Aortic Valve | 4 | 2003 | 249 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 529 | 0.100 |
Why?
|
| Terminal Care | 1 | 2012 | 92 | 0.100 |
Why?
|
| Quail | 3 | 2000 | 27 | 0.100 |
Why?
|
| Propranolol | 1 | 1991 | 103 | 0.100 |
Why?
|
| Physical Endurance | 1 | 2011 | 38 | 0.100 |
Why?
|
| Caffeine | 1 | 1991 | 81 | 0.100 |
Why?
|
| Aortic Diseases | 1 | 2012 | 113 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2012 | 238 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2012 | 215 | 0.090 |
Why?
|
| Autophagy | 1 | 2012 | 208 | 0.090 |
Why?
|
| Prostheses and Implants | 2 | 2008 | 159 | 0.090 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2010 | 27 | 0.090 |
Why?
|
| Adolescent | 8 | 2022 | 8912 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2011 | 1342 | 0.090 |
Why?
|
| Telemedicine | 1 | 2018 | 700 | 0.090 |
Why?
|
| Sirolimus | 1 | 2011 | 118 | 0.090 |
Why?
|
| Hypertrophy | 4 | 2012 | 89 | 0.090 |
Why?
|
| Postoperative Period | 5 | 1998 | 238 | 0.090 |
Why?
|
| Sweden | 2 | 2020 | 21 | 0.090 |
Why?
|
| North America | 2 | 2020 | 112 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2008 | 195 | 0.090 |
Why?
|
| Microscopy, Electron | 4 | 2000 | 351 | 0.080 |
Why?
|
| Regression Analysis | 3 | 2017 | 737 | 0.080 |
Why?
|
| Cytoskeleton | 3 | 2000 | 84 | 0.080 |
Why?
|
| Vascular Stiffness | 3 | 2014 | 31 | 0.080 |
Why?
|
| Chi-Square Distribution | 3 | 2016 | 546 | 0.080 |
Why?
|
| Coturnix | 2 | 1999 | 22 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2005 | 317 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2020 | 411 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 1174 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 331 | 0.080 |
Why?
|
| Proteome | 1 | 2009 | 87 | 0.080 |
Why?
|
| Latin America | 2 | 2018 | 19 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 2324 | 0.080 |
Why?
|
| Tissue Scaffolds | 1 | 2009 | 111 | 0.080 |
Why?
|
| Coronary Artery Bypass | 3 | 2012 | 218 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 86 | 0.080 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2007 | 15 | 0.070 |
Why?
|
| Constriction, Pathologic | 3 | 2012 | 236 | 0.070 |
Why?
|
| Isotonic Contraction | 1 | 1987 | 4 | 0.070 |
Why?
|
| Diacetyl | 2 | 1998 | 6 | 0.070 |
Why?
|
| Egtazic Acid | 2 | 1998 | 29 | 0.070 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 2077 | 0.070 |
Why?
|
| Epidemiologic Research Design | 1 | 2007 | 5 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2007 | 82 | 0.070 |
Why?
|
| Capillaries | 3 | 1992 | 105 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 196 | 0.070 |
Why?
|
| United Kingdom | 2 | 2018 | 152 | 0.070 |
Why?
|
| Infusions, Intravenous | 3 | 2016 | 334 | 0.070 |
Why?
|
| Angina, Unstable | 1 | 2006 | 50 | 0.070 |
Why?
|
| Myocardial Revascularization | 2 | 2017 | 56 | 0.070 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2006 | 43 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 689 | 0.070 |
Why?
|
| Cell Size | 2 | 1998 | 76 | 0.070 |
Why?
|
| Ventricular Dysfunction | 1 | 2006 | 15 | 0.070 |
Why?
|
| Coronary Angiography | 4 | 2017 | 866 | 0.070 |
Why?
|
| Hydrochlorothiazide | 1 | 2006 | 15 | 0.070 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2014 | 100 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2022 | 239 | 0.070 |
Why?
|
| Endpoint Determination | 3 | 2016 | 82 | 0.070 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2006 | 24 | 0.070 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2006 | 69 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2011 | 514 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2016 | 682 | 0.070 |
Why?
|
| Physical Exertion | 1 | 2006 | 75 | 0.070 |
Why?
|
| Albuminuria | 2 | 2018 | 171 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2020 | 216 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 349 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 160 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2005 | 121 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 373 | 0.060 |
Why?
|
| Recurrence | 2 | 2018 | 948 | 0.060 |
Why?
|
| Caspase 3 | 3 | 2011 | 233 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 772 | 0.060 |
Why?
|
| Thiazoles | 1 | 2005 | 95 | 0.060 |
Why?
|
| Tensile Strength | 2 | 2009 | 90 | 0.060 |
Why?
|
| Tacrolimus | 1 | 2005 | 127 | 0.060 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2004 | 40 | 0.060 |
Why?
|
| Constriction | 2 | 2002 | 37 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2017 | 118 | 0.060 |
Why?
|
| Nitroglycerin | 3 | 1997 | 20 | 0.060 |
Why?
|
| Hypothermia, Induced | 2 | 1995 | 93 | 0.060 |
Why?
|
| Canada | 2 | 2014 | 267 | 0.060 |
Why?
|
| Logistic Models | 2 | 2018 | 1420 | 0.060 |
Why?
|
| Inpatients | 2 | 2020 | 208 | 0.060 |
Why?
|
| Prosthesis Design | 2 | 2018 | 301 | 0.060 |
Why?
|
| Guanosine Monophosphate | 1 | 2023 | 1 | 0.050 |
Why?
|
| Ligation | 2 | 2008 | 83 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2006 | 450 | 0.050 |
Why?
|
| Body Weight | 4 | 2015 | 554 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2016 | 144 | 0.050 |
Why?
|
| Contractile Proteins | 1 | 2002 | 17 | 0.050 |
Why?
|
| Adenosine | 3 | 1992 | 165 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 109 | 0.050 |
Why?
|
| New York | 1 | 2023 | 223 | 0.050 |
Why?
|
| Tretinoin | 2 | 2000 | 92 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2005 | 229 | 0.050 |
Why?
|
| Bioreactors | 1 | 2023 | 65 | 0.050 |
Why?
|
| Ventricular Fibrillation | 1 | 2023 | 85 | 0.050 |
Why?
|
| Hydroxyproline | 1 | 2002 | 33 | 0.050 |
Why?
|
| GATA4 Transcription Factor | 2 | 2000 | 33 | 0.050 |
Why?
|
| Los Angeles | 1 | 2002 | 30 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2014 | 1034 | 0.050 |
Why?
|
| Ferricyanides | 3 | 1987 | 4 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2003 | 248 | 0.050 |
Why?
|
| Linear Models | 2 | 2014 | 521 | 0.050 |
Why?
|
| Remote Sensing Technology | 1 | 2021 | 4 | 0.050 |
Why?
|
| Forecasting | 2 | 2014 | 277 | 0.050 |
Why?
|
| Cell Survival | 2 | 2009 | 901 | 0.050 |
Why?
|
| Receptors, Endothelin | 1 | 2001 | 30 | 0.050 |
Why?
|
| Homeodomain Proteins | 2 | 1999 | 157 | 0.050 |
Why?
|
| Adenosine Triphosphate | 4 | 1991 | 314 | 0.050 |
Why?
|
| Fibronectins | 3 | 2012 | 130 | 0.050 |
Why?
|
| Receptors, Angiotensin | 2 | 1998 | 59 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2020 | 45 | 0.050 |
Why?
|
| Least-Squares Analysis | 1 | 2020 | 35 | 0.050 |
Why?
|
| Guanylate Cyclase | 1 | 2020 | 25 | 0.050 |
Why?
|
| Phantoms, Imaging | 1 | 2022 | 189 | 0.050 |
Why?
|
| Gene Expression | 3 | 2003 | 770 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2001 | 223 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2013 | 880 | 0.050 |
Why?
|
| Vitamin A | 2 | 1999 | 111 | 0.050 |
Why?
|
| Length of Stay | 2 | 2015 | 780 | 0.050 |
Why?
|
| Random Allocation | 3 | 2015 | 442 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2000 | 62 | 0.040 |
Why?
|
| Guanylyl Cyclase C Agonists | 1 | 2020 | 1 | 0.040 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2011 | 40 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 149 | 0.040 |
Why?
|
| Digestive System | 1 | 2000 | 35 | 0.040 |
Why?
|
| Somites | 1 | 2000 | 6 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 951 | 0.040 |
Why?
|
| Endoderm | 1 | 2000 | 37 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2020 | 217 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1999 | 38 | 0.040 |
Why?
|
| Heart Conduction System | 1 | 2020 | 119 | 0.040 |
Why?
|
| Patients | 1 | 2020 | 69 | 0.040 |
Why?
|
| Warfarin | 1 | 2020 | 93 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 377 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1054 | 0.040 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1999 | 19 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2020 | 98 | 0.040 |
Why?
|
| Cardiomyopathy, Alcoholic | 1 | 2019 | 2 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2002 | 1140 | 0.040 |
Why?
|
| Dangerous Behavior | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2019 | 12 | 0.040 |
Why?
|
| Electrophysiology | 1 | 1999 | 160 | 0.040 |
Why?
|
| Angioedema | 1 | 2019 | 41 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2000 | 214 | 0.040 |
Why?
|
| Limb Buds | 1 | 1999 | 8 | 0.040 |
Why?
|
| Peripartum Period | 1 | 2019 | 15 | 0.040 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2019 | 51 | 0.040 |
Why?
|
| Organelle Biogenesis | 1 | 2019 | 34 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2019 | 34 | 0.040 |
Why?
|
| Homeobox Protein Nkx-2.5 | 1 | 1999 | 27 | 0.040 |
Why?
|
| Ovum | 1 | 1999 | 24 | 0.040 |
Why?
|
| Captopril | 1 | 1999 | 22 | 0.040 |
Why?
|
| Wnt Proteins | 2 | 2015 | 57 | 0.040 |
Why?
|
| Virus Diseases | 1 | 2019 | 31 | 0.040 |
Why?
|
| Asia, Western | 1 | 2018 | 1 | 0.040 |
Why?
|
| Europe, Eastern | 1 | 2018 | 1 | 0.040 |
Why?
|
| Asia, Southeastern | 1 | 2018 | 5 | 0.040 |
Why?
|
| Quebec | 1 | 2018 | 2 | 0.040 |
Why?
|
| Weight Loss | 1 | 2021 | 319 | 0.040 |
Why?
|
| Body Patterning | 1 | 1999 | 44 | 0.040 |
Why?
|
| Biological Availability | 1 | 2019 | 79 | 0.040 |
Why?
|
| Heparin | 2 | 1997 | 205 | 0.040 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 1998 | 9 | 0.040 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 32 | 0.040 |
Why?
|
| Chagas Disease | 1 | 2018 | 8 | 0.040 |
Why?
|
| Retinoid X Receptors | 1 | 1998 | 26 | 0.040 |
Why?
|
| Physical Examination | 1 | 2019 | 152 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 2009 | 215 | 0.040 |
Why?
|
| Sepharose | 1 | 1998 | 18 | 0.040 |
Why?
|
| Ethanol | 1 | 2005 | 893 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 107 | 0.040 |
Why?
|
| Antigens, CD | 1 | 1999 | 230 | 0.040 |
Why?
|
| Gels | 1 | 1998 | 55 | 0.040 |
Why?
|
| Cell Physiological Phenomena | 1 | 1998 | 19 | 0.040 |
Why?
|
| Sus scrofa | 1 | 2018 | 74 | 0.040 |
Why?
|
| Actin Cytoskeleton | 1 | 1998 | 37 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2019 | 199 | 0.040 |
Why?
|
| Heart Valve Diseases | 1 | 2019 | 123 | 0.040 |
Why?
|
| Isotope Labeling | 2 | 2009 | 30 | 0.040 |
Why?
|
| Developing Countries | 1 | 2019 | 106 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 320 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2014 | 235 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2017 | 17 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 231 | 0.040 |
Why?
|
| Down-Regulation | 1 | 1999 | 447 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2017 | 48 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2018 | 108 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 84 | 0.040 |
Why?
|
| Trans-Activators | 1 | 1999 | 237 | 0.040 |
Why?
|
| Adenylyl Cyclases | 2 | 1994 | 94 | 0.040 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 1997 | 20 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2017 | 103 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2018 | 144 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 507 | 0.040 |
Why?
|
| Thoracic Vertebrae | 1 | 1997 | 52 | 0.040 |
Why?
|
| Radiography, Interventional | 1 | 1997 | 49 | 0.040 |
Why?
|
| Amnesia | 1 | 2016 | 17 | 0.040 |
Why?
|
| Confusion | 1 | 2016 | 20 | 0.040 |
Why?
|
| Monocytes | 1 | 2018 | 210 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 438 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 1996 | 134 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 1997 | 138 | 0.030 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 1996 | 37 | 0.030 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2016 | 28 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2016 | 19 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2020 | 448 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2016 | 26 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2006 | 50 | 0.030 |
Why?
|
| Polymers | 1 | 1998 | 244 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1999 | 384 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 362 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2016 | 85 | 0.030 |
Why?
|
| Blood Urea Nitrogen | 1 | 2016 | 65 | 0.030 |
Why?
|
| Delirium | 1 | 2016 | 45 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2016 | 47 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2017 | 239 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2016 | 144 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 563 | 0.030 |
Why?
|
| Neutral Ceramidase | 1 | 2016 | 27 | 0.030 |
Why?
|
| Aminopropionitrile | 1 | 1995 | 3 | 0.030 |
Why?
|
| Lisinopril | 1 | 2015 | 16 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2015 | 51 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2016 | 94 | 0.030 |
Why?
|
| Chemokine CX3CL1 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2015 | 9 | 0.030 |
Why?
|
| Norepinephrine | 2 | 1993 | 276 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2279 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2015 | 16 | 0.030 |
Why?
|
| Vascular Resistance | 2 | 1992 | 179 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2015 | 38 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2015 | 23 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 1995 | 80 | 0.030 |
Why?
|
| Liver | 2 | 2020 | 1118 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2015 | 20 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1995 | 282 | 0.030 |
Why?
|
| Intracellular Membranes | 1 | 1995 | 86 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2016 | 111 | 0.030 |
Why?
|
| Genes, Immediate-Early | 1 | 1995 | 13 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 1752 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2014 | 5 | 0.030 |
Why?
|
| Russia | 1 | 2014 | 8 | 0.030 |
Why?
|
| Alabama | 1 | 2015 | 98 | 0.030 |
Why?
|
| Troponin | 1 | 2014 | 25 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 1 | 2014 | 28 | 0.030 |
Why?
|
| Triiodothyronine, Reverse | 1 | 1994 | 4 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 189 | 0.030 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2014 | 60 | 0.030 |
Why?
|
| Immediate-Early Proteins | 1 | 1995 | 63 | 0.030 |
Why?
|
| Colforsin | 1 | 1994 | 42 | 0.030 |
Why?
|
| Critical Care | 1 | 1997 | 263 | 0.030 |
Why?
|
| Massachusetts | 1 | 2014 | 28 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 99 | 0.030 |
Why?
|
| Vascular Patency | 1 | 2014 | 122 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2008 | 160 | 0.030 |
Why?
|
| Protamines | 1 | 1994 | 14 | 0.030 |
Why?
|
| Phosphocreatine | 3 | 1990 | 20 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2014 | 108 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 1995 | 112 | 0.030 |
Why?
|
| Collagen Type III | 1 | 2014 | 21 | 0.030 |
Why?
|
| Young Adult | 2 | 2015 | 5717 | 0.030 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2014 | 19 | 0.030 |
Why?
|
| Discoidin Domain Receptors | 1 | 2014 | 16 | 0.030 |
Why?
|
| Collagen Type IV | 1 | 2014 | 28 | 0.030 |
Why?
|
| Receptors, Mitogen | 1 | 2014 | 23 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 786 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 135 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 274 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1992 | 219 | 0.030 |
Why?
|
| Microscopy, Confocal | 3 | 2000 | 337 | 0.030 |
Why?
|
| Sample Size | 1 | 2013 | 79 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 1994 | 231 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 107 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2014 | 175 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2006 | 275 | 0.030 |
Why?
|
| Myristic Acid | 1 | 2012 | 6 | 0.030 |
Why?
|
| Body Water | 1 | 1992 | 35 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 170 | 0.030 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2012 | 15 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2012 | 25 | 0.030 |
Why?
|
| Radioligand Assay | 1 | 1992 | 109 | 0.030 |
Why?
|
| Smoking | 1 | 2021 | 1452 | 0.030 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2012 | 18 | 0.030 |
Why?
|
| Troponin I | 1 | 2012 | 34 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2012 | 42 | 0.030 |
Why?
|
| Models, Structural | 1 | 1992 | 22 | 0.030 |
Why?
|
| Cardiac Glycosides | 1 | 1992 | 8 | 0.030 |
Why?
|
| Survivors | 1 | 2014 | 256 | 0.030 |
Why?
|
| Ouabain | 1 | 1992 | 32 | 0.030 |
Why?
|
| Minnesota | 1 | 2012 | 27 | 0.030 |
Why?
|
| Arterioles | 1 | 1992 | 40 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 373 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 1997 | 498 | 0.020 |
Why?
|
| Arteries | 1 | 2012 | 108 | 0.020 |
Why?
|
| Mathematics | 1 | 1991 | 83 | 0.020 |
Why?
|
| Body Size | 1 | 2011 | 39 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 1992 | 396 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 306 | 0.020 |
Why?
|
| Child | 2 | 2022 | 6405 | 0.020 |
Why?
|
| Lactates | 2 | 1990 | 29 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 595 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2011 | 104 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1996 | 2083 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 216 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2012 | 183 | 0.020 |
Why?
|
| Kinetics | 1 | 1992 | 1047 | 0.020 |
Why?
|
| Vitronectin | 2 | 2000 | 12 | 0.020 |
Why?
|
| Colloids | 1 | 2010 | 43 | 0.020 |
Why?
|
| Heart Arrest, Induced | 1 | 1990 | 52 | 0.020 |
Why?
|
| Rats, Inbred WKY | 1 | 1990 | 48 | 0.020 |
Why?
|
| Base Sequence | 2 | 2006 | 1015 | 0.020 |
Why?
|
| DNA | 1 | 1992 | 597 | 0.020 |
Why?
|
| Postoperative Care | 1 | 1991 | 163 | 0.020 |
Why?
|
| Rats, Inbred SHR | 1 | 1990 | 95 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2012 | 384 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 1991 | 174 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 252 | 0.020 |
Why?
|
| Posture | 1 | 2010 | 107 | 0.020 |
Why?
|
| Energy Metabolism | 2 | 1991 | 222 | 0.020 |
Why?
|
| Hexuronic Acids | 1 | 2009 | 24 | 0.020 |
Why?
|
| Glucuronic Acid | 1 | 2009 | 25 | 0.020 |
Why?
|
| Particle Size | 1 | 2010 | 201 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 630 | 0.020 |
Why?
|
| Neutrophils | 1 | 2010 | 204 | 0.020 |
Why?
|
| Gold | 1 | 2010 | 76 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2009 | 87 | 0.020 |
Why?
|
| Alginates | 1 | 2009 | 35 | 0.020 |
Why?
|
| Sphingolipids | 1 | 2012 | 337 | 0.020 |
Why?
|
| Databases, Protein | 1 | 2009 | 49 | 0.020 |
Why?
|
| Internationality | 1 | 2009 | 74 | 0.020 |
Why?
|
| Anesthesia | 1 | 1991 | 120 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 1447 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2009 | 47 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2009 | 65 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 363 | 0.020 |
Why?
|
| Hydrogels | 1 | 2009 | 54 | 0.020 |
Why?
|
| Computer-Aided Design | 1 | 2009 | 101 | 0.020 |
Why?
|
| Walking | 1 | 2011 | 241 | 0.020 |
Why?
|
| Gelsolin | 1 | 2008 | 6 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2008 | 51 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2008 | 24 | 0.020 |
Why?
|
| Blood Pressure Monitors | 1 | 2008 | 2 | 0.020 |
Why?
|
| Vasodilation | 1 | 2008 | 85 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2008 | 36 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 226 | 0.020 |
Why?
|
| Dextrans | 1 | 1987 | 33 | 0.020 |
Why?
|
| Cricetinae | 1 | 2008 | 262 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 2007 | 81 | 0.020 |
Why?
|
| Histones | 1 | 2008 | 111 | 0.020 |
Why?
|
| Perfusion | 1 | 1987 | 131 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 245 | 0.020 |
Why?
|
| Digitalis Glycosides | 1 | 2006 | 5 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 306 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 432 | 0.020 |
Why?
|
| Gelatinases | 1 | 2006 | 12 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2006 | 95 | 0.020 |
Why?
|
| Models, Biological | 2 | 2008 | 981 | 0.020 |
Why?
|
| Sinoatrial Node | 1 | 2006 | 14 | 0.020 |
Why?
|
| Transgenes | 1 | 2006 | 92 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2006 | 52 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2006 | 242 | 0.020 |
Why?
|
| Diabetic Angiopathies | 1 | 2008 | 203 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2006 | 191 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2006 | 176 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2006 | 295 | 0.020 |
Why?
|
| Radionuclide Imaging | 4 | 1987 | 166 | 0.020 |
Why?
|
| Temperature | 1 | 1987 | 341 | 0.020 |
Why?
|
| Genotype | 1 | 2008 | 786 | 0.020 |
Why?
|
| Syndrome | 1 | 2006 | 255 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 137 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2005 | 242 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 284 | 0.020 |
Why?
|
| Metalloendopeptidases | 1 | 2005 | 67 | 0.020 |
Why?
|
| Necrosis | 1 | 2005 | 239 | 0.020 |
Why?
|
| Heart Septum | 1 | 2005 | 84 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2006 | 233 | 0.010 |
Why?
|
| Radiography | 1 | 2005 | 572 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2004 | 65 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2003 | 57 | 0.010 |
Why?
|
| Isomerism | 1 | 2003 | 63 | 0.010 |
Why?
|
| Weight-Bearing | 1 | 2003 | 53 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 2 | 1981 | 157 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 2003 | 58 | 0.010 |
Why?
|
| Radionuclide Ventriculography | 1 | 2001 | 6 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 2000 | 13 | 0.010 |
Why?
|
| Dipyridamole | 1 | 2000 | 26 | 0.010 |
Why?
|
| Dobutamine | 1 | 2000 | 25 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2000 | 27 | 0.010 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2000 | 26 | 0.010 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2000 | 26 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 2000 | 35 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2000 | 92 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 1981 | 180 | 0.010 |
Why?
|
| Cold Temperature | 1 | 2000 | 90 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2000 | 114 | 0.010 |
Why?
|
| GATA5 Transcription Factor | 1 | 2000 | 6 | 0.010 |
Why?
|
| Chimera | 1 | 2000 | 33 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2000 | 150 | 0.010 |
Why?
|
| Microtomy | 1 | 2000 | 11 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1981 | 135 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2000 | 147 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 2001 | 122 | 0.010 |
Why?
|
| GATA6 Transcription Factor | 1 | 2000 | 27 | 0.010 |
Why?
|
| Tyrosine | 1 | 2000 | 196 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2000 | 122 | 0.010 |
Why?
|
| Embryo, Nonmammalian | 1 | 2000 | 64 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1999 | 43 | 0.010 |
Why?
|
| Polypharmacy | 1 | 1999 | 31 | 0.010 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 1999 | 2 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 250 | 0.010 |
Why?
|
| Cell Count | 1 | 2000 | 248 | 0.010 |
Why?
|
| Chick Embryo | 1 | 2000 | 379 | 0.010 |
Why?
|
| Actins | 1 | 2000 | 249 | 0.010 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 1999 | 10 | 0.010 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 1999 | 4 | 0.010 |
Why?
|
| Integrin beta1 | 1 | 1999 | 48 | 0.010 |
Why?
|
| Fibroblast Growth Factor 8 | 1 | 1999 | 7 | 0.010 |
Why?
|
| Culture Media | 1 | 1999 | 155 | 0.010 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 1999 | 43 | 0.010 |
Why?
|
| Hedgehog Proteins | 1 | 1999 | 38 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1999 | 282 | 0.010 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 1999 | 57 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 1999 | 51 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1981 | 434 | 0.010 |
Why?
|
| Polyribosomes | 1 | 1998 | 24 | 0.010 |
Why?
|
| Leucine | 1 | 1998 | 41 | 0.010 |
Why?
|
| Ribosomes | 1 | 1998 | 23 | 0.010 |
Why?
|
| Biopolymers | 1 | 1998 | 21 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 1981 | 756 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 1998 | 80 | 0.010 |
Why?
|
| Protein Binding | 1 | 2000 | 1027 | 0.010 |
Why?
|
| Heterozygote | 1 | 1998 | 174 | 0.010 |
Why?
|
| Peptides | 1 | 2000 | 455 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1999 | 411 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1998 | 562 | 0.010 |
Why?
|
| Imidazoles | 1 | 1996 | 175 | 0.010 |
Why?
|
| Cell Division | 1 | 1996 | 541 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1995 | 35 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 1995 | 17 | 0.010 |
Why?
|
| Genes, fos | 1 | 1995 | 22 | 0.010 |
Why?
|
| Catecholamines | 1 | 1995 | 73 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2000 | 596 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 1995 | 42 | 0.010 |
Why?
|
| Carotenoids | 1 | 1974 | 45 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1994 | 29 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1995 | 114 | 0.010 |
Why?
|
| Blood Viscosity | 1 | 1994 | 9 | 0.010 |
Why?
|
| Sarcolemma | 1 | 1993 | 16 | 0.010 |
Why?
|
| Immunologic Techniques | 2 | 1981 | 30 | 0.010 |
Why?
|
| Angioplasty, Balloon | 1 | 1992 | 110 | 0.010 |
Why?
|
| Electrolytes | 1 | 1991 | 47 | 0.010 |
Why?
|
| Lactic Acid | 1 | 1990 | 86 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1991 | 618 | 0.010 |
Why?
|
| Computer Simulation | 1 | 1991 | 706 | 0.000 |
Why?
|
| South Carolina | 1 | 1992 | 2752 | 0.000 |
Why?
|
| Intrinsic Factor | 1 | 1981 | 3 | 0.000 |
Why?
|
| Blood Sedimentation | 1 | 1981 | 16 | 0.000 |
Why?
|
| Rheumatoid Factor | 1 | 1981 | 21 | 0.000 |
Why?
|
| Synovial Fluid | 1 | 1981 | 16 | 0.000 |
Why?
|
| Complement Pathway, Classical | 1 | 1981 | 22 | 0.000 |
Why?
|
| Complement Pathway, Alternative | 1 | 1981 | 69 | 0.000 |
Why?
|
| Antibodies, Antinuclear | 1 | 1981 | 171 | 0.000 |
Why?
|
| Antibodies | 1 | 1981 | 241 | 0.000 |
Why?
|
| Complement Activation | 1 | 1981 | 145 | 0.000 |
Why?
|
| Pregnancy | 1 | 1981 | 2334 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1981 | 2455 | 0.000 |
Why?
|
| Palmitic Acids | 1 | 1974 | 15 | 0.000 |
Why?
|
| Ethers | 1 | 1974 | 13 | 0.000 |
Why?
|
| Carbon Radioisotopes | 1 | 1974 | 34 | 0.000 |
Why?
|
| Infant | 1 | 1981 | 2891 | 0.000 |
Why?
|
| Methods | 1 | 1974 | 156 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1974 | 79 | 0.000 |
Why?
|
| Testis | 1 | 1974 | 37 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1981 | 3187 | 0.000 |
Why?
|
| Acetates | 1 | 1974 | 74 | 0.000 |
Why?
|
| Intestine, Small | 1 | 1974 | 89 | 0.000 |
Why?
|
| Polysaccharides | 1 | 1974 | 176 | 0.000 |
Why?
|
| Skin | 1 | 1974 | 451 | 0.000 |
Why?
|